EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Denosumab discontinuation and fracture risk: getting the balance right

Albert S Kim iD, Christian M Girgis iD

Internal Medicine Journal · 24.06.2026

DOI: 10.1111/imj.70519 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Internal Medicine Journal, online erschienen am 24.06.2026. Verfasst von Albert S Kim und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Westmead Hospital, Sydney, New South Wales, Australia. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Denosumab is a highly effective therapy for osteoporosis. Since its approval by the Therapeutic Goods Administration (TGA) in 2010, use of denosumab has surged across Australia, delivering substantial fracture‐prevention benefits to tens of thousands of patients. However, stopping denosumab may lead to acute loss of bone with an increased risk of fractures. Increasing awareness of this so‐called ‘rebound phenomenon’ has created fear and concern among consumers and prescribers. A recent TGA safety update in November 2025 has raised further concern regarding the risk of spontaneous vertebral fractures in patients ceasing denosumab. This Viewpoint aims to interpret the latest updates in the context of current evidence, examine why Australia is particularly vulnerable to misinterpretation of these warnings and provide practical guidance to support safe, evidence‐based management of denosumab use in Australian practice.

Schlagwörter

Stichwörter der Autor:innen

denosumabfracturesmedication safetyosteoporosis

Autor:innen und Institutionen

  • Department of Endocrinology, Westmead Hospital, Sydney, New South Wales, Australia.
  • Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.

ORCID-Profile: Albert S Kim, Christian M Girgis

Zitieren

APA

Kim, A. S., & Girgis, C. M. (2026). Denosumab discontinuation and fracture risk: getting the balance right. Internal Medicine Journal. https://doi.org/10.1111/imj.70519

Vancouver

Kim AS, Girgis CM. Denosumab discontinuation and fracture risk: getting the balance right. Internal Medicine Journal. 2026. doi:10.1111/imj.70519

BibTeX
@article{Kim2026,
  author = {Kim, Albert S and Girgis, Christian M},
  title = {Denosumab discontinuation and fracture risk: getting the balance right},
  journal = {Internal Medicine Journal},
  year = {2026},
  doi = {10.1111/imj.70519}
}
Kostenlos starten →